Detail

Study ID: COG AALL1732

Title:

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL; Risk Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Location:
Fargo Region, Sioux Falls Region
Principal Investigator:
Kayelyn Wagner, MD,Samuel Anim, MD
Disease:
ALL (Acute Lymphocytic Leukemia)
Stage:
Phase III
Status:
Active - Open to Accrual